Parkinson's Disease Pipeline, FDA Approvals, Clinical Trials Developments and Companies (Updated)

DelveInsight's, "Parkinson's Disease Pipeline Insight" report provides comprehensive insights about 140+ Parkinson's Disease companies and 150+ pipeline drugs in Parkinson's Disease pipeline landscape. It covers the Parkinson's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Parkinson's Disease Pipeline Report
• DelveInsight's Parkinson's Disease pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Parkinson's Disease treatment.
• The leading Parkinson's Disease companies working in the market include Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
• Promising Parkinson's Disease Pipeline Therapies in the various stages of development include BIIB122, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, KM-819, and others.
• December 2023: AC Immune SA announced a study of Phase 2 clinical trials for ACI-7104.056 at Dose A. The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 vaccination in patients with early stages of Parkinson's disease. This is a prospective, multicenter, placebo-controlled, double-blind, randomized study with adaptive features, comprising a screening period of up to 8 weeks, a 74-week double-blind treatment period, and a 26-week post-treatment follow-up period.
• December 2023: Prevail Therapeutics announced a study of phase 1 & 2 clinical trials for Methylprednisolone and Sirolimus. A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL).
• July 2023: Hoffmann-La Roche announced a study of phase 2 clinical trials for Prasinezumab. This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.
• March 2023: Neurocrine Biosciences announced a study of phase 2 clinical trials for VY-AADC02. The objectives of this study are to assess the efficacy, safety and tolerability of VY-AADC02 in Patients with Parkinson's Disease with Motor Fluctuations.

Request a sample and discover the recent advances in Parkinson's Disease Treatment Drugs @ Parkinson's Disease Pipeline Outlook Report- https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Parkinson's Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson's disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Parkinson's Disease Overview
Parkinson's disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine.

Find out more about Parkinson's Disease Treatment Landscape @ Drugs for Parkinson's Disease Treatment- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Parkinson's Disease Emerging Drugs Profile
• Tavapadon: Cerevel Therapeutics
• IkT-148009: Inhibikase Therapeutics
• NLY01: Neuraly
• PT320: Peptron

Parkinson's Disease Pipeline Therapeutics Assessment
There are approx. 140+ key Parkinson's Disease companies which are developing the Parkinson's Disease therapies. The Parkinson's Disease companies which have their Parkinson's disease drug candidates in the most advanced stage, i.e. phase III include, Cerevel Therapeutics.

DelveInsight's Parkinson's Disease pipeline report covers around 150+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Parkinson's disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Parkinson's Disease Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Parkinson's Disease Pipeline Therapies @ Parkinson's Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Parkinson's Disease Pipeline Report
• Coverage- Global
• Parkinson's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Parkinson's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Parkinson's Disease Companies- Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
• Parkinson's Disease Pipeline Therapies- BIIB122, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, KM-819, and others.

Dive deep into rich insights for new drugs for Parkinson's Disease treatment, Visit @ Parkinson's Disease Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Parkinson's Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Parkinson's Disease - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tavapadon: Cerevel Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Prasinezumab : Roche
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MEDI1341: AstraZeneca
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Neural microtissues: Treefrog Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Parkinson's Disease Companies
21. Parkinson's Disease Products
22. Parkinson's Disease Unmet Needs
23. Parkinson's Disease Market Drivers and Barriers
24. Parkinson's Disease Future Perspectives and Conclusion
25. Parkinson's Disease Analyst Views
26. Parkinson's Disease Companies
27. Appendix

For further information on the Parkinson's Disease pipeline therapeutics, reach out to Parkinson's Disease Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Published Links

https://connectgalaxy.com/post/146081_syphilis-a-sexually-transmitted-bacterial-infection-caused-by-treponema-pallidum.html
https://www.thebostoncalendar.com/user/74833
https://wrongplanet.net/author/dennydones9999/
https://bookmark.hiauthors.com/story/syphilis-market
https://www.openhumans.org/member/anniethomas/
https://cynochat.com/read-blog/160375
https://hitrecord.org/users/dennydones9999/records
https://biiut.com/read-blog/918
https://nimmansocial.com/story5840956/syphilis-market
https://bookmarkbirth.com/story15878475/syphilis-market
https://biomolecula.ru/authors/25303
https://discuss.machform.com/u/dennydones9191
https://dagshub.com/dennydones9191
https://careerkarma.com/profile/clr7d7z0c04v2lf3k5lrx9vyr/
https://gotech.mn.co/posts/48477911
https://landmarknew.mn.co/posts/48477947
https://infiniteabundance.mn.co/posts/48478016
https://wellbeingmatters.mn.co/posts/48478424
https://vrjam.mn.co/posts/48478544
https://decidim.santcugat.cat/profiles/dennydones9/activity
https://haveagood.holiday/users/336105
https://participa.rubi.cat/profiles/dennydones9191/activity
https://forum.callofwar.com/index.php?user/60304-dennydones9191/#about
https://kktix.com/user/5068280
https://network-373.mn.co/posts/48353213
https://body-imagine.mn.co/posts/48353364
https://pimpmyairgun.mn.co/posts/48353478
https://gtribe.mn.co/posts/advancements-and-opportunities-in-the-vulvar-cancer-market
https://communenour.mn.co/posts/emerging-trends-and-market-dynamics-in-vulvar-cancer-treatment
https://synkretic.mn.co/posts/understanding-the-vulvar-cancer-market-trends-challenges-and-innovations
https://jlfa2020.mn.co/members/16644457
https://dbook.mn.co/posts/48401881
https://lxgonline.mn.co/posts/navigating-the-landscape-of-hypertriglyceridemia-market-current-trends-and-future-prospects
https://www.penname.me/@dennydones99
https://community.fyers.in/member/7Yldtdsvui
https://spurstartup.mn.co/posts/48406045
https://pressurecooker.mn.co/posts/48406225
https://regenerative-future.mn.co/posts/navigating-the-hypertriglyceridemia-market-innovations-and-challenges
https://commiss.io/dennydones
https://www.pledgeme.co.nz/profiles/221820/
https://brave-comfort.mn.co/posts/48409148
https://gamebook.mn.co/posts/navigating-the-landscape-of-the-hypertriglyceridemia-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/stem-cell-market

This release was published on openPR.